把癌细胞特异性抗体作为抗癌药的载体,使抗癌药直接作用于癌细胞,这一疗法叫做癌的导弹疗法。本文对这一疗法的现状、存在的问题和发展趋势作一简述。从70年代后半叶,山口俊晴等研制出丝裂霉素C与肿瘤标记AFP抗体相结合的复合体。以后又研制出鼠单克隆抗体与新制癌菌素相结合的 The cancer-specific antibodies are used as carriers of anticancer drugs to make anticancer drugs directly act on cancer cells. This therapy is called cancer missile therapy. This article gives a brief description of the current status, existing problems and development trends of this therapy. From the latter half of the 1970s, Yamaguchi Junchi and others developed a complex of mitomycin C and tumor marker AFP antibody. Later, it developed a combination of mouse monoclonal antibodies and new carcinogens.